Clinical Trial Search

Primary: Mortality — 0; 0 percentage of mortality

Primary: QOL: Kidney Disease Quality of Life (KDQOL36) — 74; 72 score on a scale

Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04

Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%

Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21

Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants

Primary: Mean Feasibility of Intervention Measure — 16.4; 16.1; 19.0 score on a scale

Primary: Phosphocreatine (PCR) Recovery Time After Knee Extension Assessed by 31 Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) — 60.59; 62.66 seconds

Primary: Peak Oxygen Consumption — 3.07 ml/min/kg

Primary: Patient Activation Measure (PAM) -13 Item Questionnaire — 9.1; -1.4 points — p=0.01

Primary: Phosphorus Levels — 5.3; 5.6; 5.4; 6 mg/dL

Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001

Primary: Patients' Adherence to Study Protocol — 22; 24; 19; 19 Participants

Primary: Incidence of Pre-dialysis HK After the LIDP in <3K Dialysate Patients — 50; 37 Percent of participants

Primary: The Patient Activation Measure (PAM) — 60.8; 61.5; 1.73; 3.44 score on a scale

Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg

Primary: Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 2 (Month 1) — 23 participants

Primary: Factors That Are Most Important to Patients — 98; 93; 97; 100 % of patients

Primary: the Occurrence of Cardiovascular Event and Peritonitis Events — 0; 0; 0; 0 participants — p=>0.05

Primary: Post-dialysis Recovery Time — 278.02 minutes

Primary: Qualitative Survey Assessmentof Perceived Usefulness of the Med-alert Device. — 1 Likert scale

Primary: Percentage of Participants Who Maintained Average Hb Value Within Target Range During the EEP — 50.0 percentage of participants

Primary: Systolic Blood Pressure (SBP) — 135.1; 134.4 mmHg — p=0.57

Primary: Mean Absolute Relative Difference Between CGM Value and Capillary Blood Glucose (Self-monitoring Blood Glucose [SMBG]) — 13.8 percent difference

Primary: The Change in Serum Phosphorus for MCI-196 and Sevelamer — -1.23; -1.47; -2.26 mg / dL

Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants

Primary: Difference in A1c Levels — 8.86; 8.21; 7.95; 8.44 percentage — p=0.00045

Primary: Number of Participants Recruited, Consented, Randomized and Completed — 51; 16; 16; 16 Participants

Primary: Medium Molecule Clearance — 53; 59.5 ml/min — p=0.4534

Primary: To Determine the Impact of Directly Observed Weekly Fluoxetine Treatment on Remission of Depression Among Hemodialysis Patients. — 6.6 units on a scale